AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31615643 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward and backward walking
Number of subjects: 22
Study 28239833 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure of mesenteric defect
Number of subjects: 2507
Study 28239833 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-closure of mesenteric defect
Number of subjects: 2507
Study 26269098 — intervention group
Group type: EXPERIMENTAL
Intervention: AVATAR therapy (7 sessions)
Number of subjects: 142
Study 26269098 — intervention group
Group type: COMPARATOR
Intervention: Supportive counselling (SC)
Number of subjects: 142
Study 23292667 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized exercise interventions during inpatient stays
Number of subjects: 0
Study 23292667 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 21974746 — intervention group
Group type: EXPERIMENTAL
Intervention: Six weekly sessions of motivational interviewing and cognitive behavioral therapy initiated approximately six weeks prior to release from prison.
Number of subjects: 0
Study 21974746 — intervention group
Group type: COMPARATOR
Intervention: Six time matched videos viewed weekly starting about six weeks prior to release (Control group).
Number of subjects: 0
Study 19303683 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of uric acid levels
Number of subjects: 838
Study 19303683 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous increase in uric acid levels (1 mg/dL)
Number of subjects: 838
Study 17530311 — intervention group
Group type: EXPERIMENTAL
Intervention: On-call counselor intervention
Number of subjects: 482
Study 17530311 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 482
Study 15207409 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care allowance for one year
Number of subjects: 109
Study 15207409 — intervention group
Group type: COMPARATOR
Intervention: Traditional geriatric ward care
Number of subjects: 109
Study 15207409 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care allowance
Number of subjects: 109
Study 15207409 — intervention group
Group type: COMPARATOR
Intervention: Home hospitalization care
Number of subjects: 109
Study 15207409 — intervention group
Group type: COMPARATOR
Intervention: Control group of 21 subjects
Number of subjects: 109
Study 12031560 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-microg misoprostol tablet placed in the posterior vaginal fornix
Number of subjects: 62
Study 12031560 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (control group)
Number of subjects: 62
Study 12031560 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (study group)
Number of subjects: 62
Study 9440664 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide 20 mg
Number of subjects: 52
Study 9440664 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide GITS 20 mg
Number of subjects: 52
Study 9440664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 9440664 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 52
Study 9440664 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide GITS
Number of subjects: 52
Study 9440664 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide and Glipizide GITS
Number of subjects: 52
Study 8078203 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU IFN daily for 2 weeks and three times weekly for 24 weeks thereafter
Number of subjects: 0
Study 8078203 — intervention group
Group type: COMPARATOR
Intervention: 1 MU IFN
Number of subjects: 0
Study 8078203 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 2775607 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg DUP 996
Number of subjects: 13
Study 2775607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 361155 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg eight-hourly plus phentolamine 20 mg three-hourly by mouth for three weeks
Number of subjects: 90
Study 361155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 27633773 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated morphine-ADER-IMT (60 mg, manipulated)
Number of subjects: 38
Study 27633773 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated morphine ER (60 mg, manipulated)
Number of subjects: 38
Study 27633773 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact morphine-ADER-IMT (60 mg, intact)
Number of subjects: 38
Study 25817884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.3 mg/kg
Number of subjects: 90
Study 25817884 — intervention group
Group type: COMPARATOR
Intervention: Morphine 0.1 mg/kg
Number of subjects: 90
Study 23660849 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 2029
Study 23660849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2029
Study 23096008 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg L-theanine via capsules
Number of subjects: 12
Study 23096008 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg L-theanine via green tea
Number of subjects: 12
Study 23096008 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg L-theanine via capsules
Number of subjects: 12
Study 23096008 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg L-theanine via capsules
Number of subjects: 12
Study 23096008 — intervention group
Group type: EXPERIMENTAL
Intervention: L-theanine (both treatments)
Number of subjects: 12
Study 19735580 — intervention group
Group type: COMPARATOR
Intervention: hLF1-11 (0.005, 0.05, 0.5, 5 mg single and multiple intravenous doses)
Number of subjects: 0
Study 19735580 — intervention group
Group type: COMPARATOR
Intervention: hLF1-11 (5 mg single intravenous dose)
Number of subjects: 0
Study 19735580 — intervention group
Group type: COMPARATOR
Intervention: hLF1-11
Number of subjects: 0
Study 17366449 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical excision
Number of subjects: 100
Study 17366449 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic therapy (clarithromycin and rifabutin for at least 12 weeks)
Number of subjects: 100
Study 17366449 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic therapy
Number of subjects: 100
Study 15208209 — intervention group
Group type: EXPERIMENTAL
Intervention: Cup feeding (cup/no dummy and cup/dummy)
Number of subjects: 319
Study 15208209 — intervention group
Group type: COMPARATOR
Intervention: Dummy use (dummy/no dummy)
Number of subjects: 319
Study 15208209 — intervention group
Group type: COMPARATOR
Intervention: Bottle feeding (bottle/no dummy and bottle/dummy)
Number of subjects: 319
Study 11204097 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximization and progress-monitoring heuristics with lookahead
Number of subjects: 0
Study 11204097 — intervention group
Group type: EXPERIMENTAL
Intervention: Extension of the model accounting for insightful moves
Number of subjects: 0
Study 11204097 — intervention group
Group type: EXPERIMENTAL
Intervention: Model predictions
Number of subjects: 0
Study 9916609 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 118
Study 9916609 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 118
Study 9916609 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 118
Study 7830855 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone treatment
Number of subjects: 29
Study 3428343 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml saline in the lumbar epidural interspace (n = 5)
Number of subjects: 23
Study 3428343 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml saline in the thoracic epidural interspace (n = 5)
Number of subjects: 23
Study 3428343 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml saline in the thoracic interspace (n = 8)
Number of subjects: 23
Study 29218817 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC decision aid (shared decision making)
Number of subjects: 898
Study 29218817 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 898
Study 27798211 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/cobicistat (300/150 mg) + daclatasvir (30 mg) once daily
Number of subjects: 16
Study 27798211 — intervention group
Group type: COMPARATOR
Intervention: Atazanavir/ritonavir (300/100 mg) + daclatasvir (30 mg) once daily
Number of subjects: 16
Study 26637210 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of mycophenolate mofetil (MMF) - 1.03 ± 0.19 g/day at 1 week
Number of subjects: 72
Study 26637210 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose of mycophenolate mofetil (MMF) - 1.48 ± 0.34 g/day at 1 week
Number of subjects: 72
Study 26637210 — intervention group
Group type: COMPARATOR
Intervention: ABO compatible KT without rituximab
Number of subjects: 72
Study 23824420 — intervention group
Group type: EXPERIMENTAL
Intervention: 54 mg genistein daily for 1 year
Number of subjects: 120
Study 23824420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 21503807 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (APAP) 975 mg
Number of subjects: 79
Study 21503807 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (IBU) 800 mg
Number of subjects: 79
Study 21503807 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Acetaminophen and Ibuprofen (APAP + IBU)
Number of subjects: 79
Study 21503807 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (IBU)
Number of subjects: 79
Study 21503807 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (APAP)
Number of subjects: 79
Study 19031496 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan (RI) 10 mg
Number of subjects: 35
Study 19031496 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (DE) 4 mg
Number of subjects: 35
Study 19031496 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan + Dexamethasone (RI+DE)
Number of subjects: 35
Study 19031496 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone + Rizatriptan (DE+RI)
Number of subjects: 35
Study 19031496 — intervention group
Group type: COMPARATOR
Intervention: Rizatriptan (RI)
Number of subjects: 35
Study 19031496 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (DE)
Number of subjects: 35
Study 17036476 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Sanyinjiao (SP 6) for 3 therapeutic courses, thrice each week, 30 min each time, for 1 month per course.
Number of subjects: 0
Study 17036476 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of nylestriol for 3 months, 2 mg each time, twice each month; medroxyprogesterone added from the third month for 7 days, 6 mg each day.
Number of subjects: 0
Study 12970830 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment-based interventions in stroke rehabilitation
Number of subjects: 403
Study 12970830 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 403
Study 12970830 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-stage level-of-evidence approach
Number of subjects: 403
Study 10962655 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tacalcitol ointment 4 micrograms/g
Number of subjects: 0
Study 8874908 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% infiltration (Group L)
Number of subjects: 168
Study 8874908 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infiltration (Group S)
Number of subjects: 168
Study 1304807 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/kg chloral hydrate with 25 mg hydroxyzine
Number of subjects: 20
Study 1304807 — intervention group
Group type: COMPARATOR
Intervention: 0.3 mg/kg temazepam
Number of subjects: 20
Study 3559574 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented total hip replacement (THR)
Number of subjects: 89
Study 3559574 — intervention group
Group type: COMPARATOR
Intervention: Cemented hemiarthroplasty (UHR‐C)
Number of subjects: 89
Study 3559574 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncemented hemiarthroplasty (UHR‐NC)
Number of subjects: 89
Study 3559574 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality rate
Number of subjects: 89
Study 3559574 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented stems
Number of subjects: 89
Study 3559574 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncemented hemiarthroplasties
Number of subjects: 89
Study 28960597 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured cricoid pressure (CP) using weighing scales to target the ideal CP range (3.060‐4.075 kg)
Number of subjects: 54
Study 28960597 — intervention group
Group type: COMPARATOR
Intervention: Control cricoid pressure where the CP operator was blinded to the amount of CP applied
Number of subjects: 54
Study 26725406 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV)
Number of subjects: 93
Study 26725406 — intervention group
Group type: EXPERIMENTAL
Intervention: Late open-lung (LOL)
Number of subjects: 93
Study 26725406 — intervention group
Group type: EXPERIMENTAL
Intervention: Early open-lung (EOL)
Number of subjects: 93
Study 24776754 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) dosed per m2 BSA
Number of subjects: 0
Study 24776754 — intervention group
Group type: COMPARATOR
Intervention: Growth Hormone (GH) dosed per kg BW
Number of subjects: 0
Study 23169946 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens alone (0.625 mg/d)
Number of subjects: 26747
Study 23169946 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (0.625 mg/d conjugated equine estrogens plus 2.5 mg/d medroxyprogesterone acetate)
Number of subjects: 26747
Study 23169946 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled analysis of both groups (E-alone and estrogen plus progestin)
Number of subjects: 26747
Study 23169946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26747
Study 20130951 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime (2 g x 2/day)
Number of subjects: 20
Study 18580148 — intervention group
Group type: EXPERIMENTAL
Intervention: End-to-side sensate coaptation using the lower lateral cutaneous brachial nerve to the tibial nerve
Number of subjects: 30
Study 18580148 — intervention group
Group type: COMPARATOR
Intervention: Control group (reconstructed without nerve coaptation)
Number of subjects: 30
Study 16580447 — intervention group
Group type: EXPERIMENTAL
Intervention: Toronto stentless porcine valve
Number of subjects: 160
Study 16580447 — intervention group
Group type: COMPARATOR
Intervention: Perimount stented bovine pericardial valve
Number of subjects: 160
Study 13680555 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockade treatment
Number of subjects: 0
Study 13680555 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocking agents with vasodilating properties
Number of subjects: 0
Study 10945430 — intervention group
Group type: EXPERIMENTAL
Intervention: Day hospital treatment
Number of subjects: 105
Study 10945430 — intervention group
Group type: COMPARATOR
Intervention: Day centre rehabilitation
Number of subjects: 105
Study 8922515 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemically cured adhesive (Lee Insta‐bond, Lee Pharmaceuticals, EI Monte, Calif.)
Number of subjects: 50
Study 8922515 — intervention group
Group type: COMPARATOR
Intervention: Visible light‐cured fluoride‐releasing material (Orthon, Orthon Dental Inc., Victoria, Canada)
Number of subjects: 50
Study 8922515 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall bond failure site evaluation
Number of subjects: 50
Study 1427414 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg aspirin/day
Number of subjects: 41
Study 1427414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 3882219 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-specific immunotherapy (ASI) with a syngeneic tumor cell:bacillus calmette-Guerin (BCG) vaccine, following surgical resection.
Number of subjects: 40
Study 3882219 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical resection alone (control).
Number of subjects: 40
Study 30937487 — intervention group
Group type: EXPERIMENTAL
Intervention: Low preoperative mental component score
Number of subjects: 756
Study 30937487 — intervention group
Group type: EXPERIMENTAL
Intervention: Low preoperative physical component score
Number of subjects: 756
Study 28328548 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC (once-weekly directly observed therapy)
Number of subjects: 12
Study 28328548 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily PrEP
Number of subjects: 12
Study 28328548 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP regimen adherence
Number of subjects: 12
Study 28328548 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC resistance testing
Number of subjects: 12
Study 28328548 — intervention group
Group type: EXPERIMENTAL
Intervention: Next generation sequencing
Number of subjects: 12
Study 25001954 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (CRT) 40 mg
Number of subjects: 20
Study 25001954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23085738 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg loading dose (LD) followed by 10 mg maintenance dose (MD) for 10 days
Number of subjects: 36
Study 23085738 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg loading dose (LD) followed by 7.5 mg maintenance dose (MD) for 10 days
Number of subjects: 36
Study 23085738 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg loading dose (LD) followed by 5 mg maintenance dose (MD) for 10 days
Number of subjects: 36
Study 19637650 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromelain at 0.25% concentration
Number of subjects: 0
Study 19637650 — intervention group
Group type: COMPARATOR
Intervention: Bromelain at 0% concentration
Number of subjects: 0
Study 17877825 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual treatment plus home exercise
Number of subjects: 480
Study 17877825 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised rehabilitative exercise plus home exercise
Number of subjects: 480
Study 17877825 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise alone
Number of subjects: 480
Study 15234276 — intervention group
Group type: EXPERIMENTAL
Intervention: Trypan blue (0.06%) staining
Number of subjects: 43
Study 15234276 — intervention group
Group type: COMPARATOR
Intervention: No trypan blue staining
Number of subjects: 43
Study 11518996 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet-Cutter
Number of subjects: 61
Study 11518996 — intervention group
Group type: COMPARATOR
Intervention: CUSA
Number of subjects: 61
Study 9745105 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary LCPUFA (arachidonate and docosahexaenoate) in infant formula
Number of subjects: 22
Study 9745105 — intervention group
Group type: COMPARATOR
Intervention: Control group (infants not receiving LCPUFA)
Number of subjects: 22
Study 7820162 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasil (ethinyl estradiol/levonorgestrel)
Number of subjects: 94
Study 7820162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho 7/7/7 (ethinyl estradiol/norethindrone)
Number of subjects: 94
Study 3342895 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 32
Study 3342895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 31611333 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate acupuncture (IA) arm
Number of subjects: 40
Study 31611333 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (CG)
Number of subjects: 40
Study 30288674 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary propionic acid (PA) 200 mg/kg of diet
Number of subjects: 240
Study 30288674 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytetracycline (OTC) 500 mg/kg of diet
Number of subjects: 240
Study 30288674 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PA and OTC
Number of subjects: 240
Study 30288674 — intervention group
Group type: COMPARATOR
Intervention: Control group (basal diet)
Number of subjects: 240
Study 28501668 — intervention group
Group type: EXPERIMENTAL
Intervention: β-lactam monotherapy
Number of subjects: 1544
Study 28501668 — intervention group
Group type: COMPARATOR
Intervention: fluoroquinolone monotherapy
Number of subjects: 1544
Study 26275160 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensatory scanning training program using horizontal scanning
Number of subjects: 49
Study 26275160 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 49
Study 23262241 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-life stress (ELS) group
Number of subjects: 69
Study 23262241 — intervention group
Group type: COMPARATOR
Intervention: Youths without a history of ELS (Control)
Number of subjects: 69
Study 21395645 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ABZ
Number of subjects: 9
Study 21395645 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg PZQ
Number of subjects: 9
Study 21395645 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ABZ + 1500 mg PZQ
Number of subjects: 9
Study 19277899 — intervention group
Group type: EXPERIMENTAL
Intervention: DFDBA with AM
Number of subjects: 10
Study 19277899 — intervention group
Group type: COMPARATOR
Intervention: BDX with AM
Number of subjects: 10
Study 17045832 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14, two dried capsules each night for 5 days
Number of subjects: 40
Study 17045832 — intervention group
Group type: COMPARATOR
Intervention: 0.75% metronidazole gel, applied vaginally twice a day for 5 days
Number of subjects: 40
Study 15565824 — intervention group
Group type: EXPERIMENTAL
Intervention: EC plus filgrastim (480 microg or 300 microg daily or every other day, on day 8 through day 14, and 300 microg daily on days 8 and 12 of each chemotherapy course)
Number of subjects: 506
Study 15565824 — intervention group
Group type: EXPERIMENTAL
Intervention: EC plus filgrastim
Number of subjects: 506
Study 15565824 — intervention group
Group type: COMPARATOR
Intervention: EC alone
Number of subjects: 506
Study 10655529 — intervention group
Group type: COMPARATOR
Intervention: Standard oral rehydration therapy
Number of subjects: 48
Study 10655529 — intervention group
Group type: COMPARATOR
Intervention: Rice flour (50 g per liter of oral rehydration solution)
Number of subjects: 48